Newsbenzinga
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
· Published
Article summary
Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.
An excerpt from the original article.
Comments —
Loading comments…